Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

alance sheet at the time paid and we were required under GAAP to amortize the deferred revenues and deferred costs into our income statement over the course of the Pfizer collaboration agreement.  We originally estimated that the life of the Pfizer agreement would be 20 years.  When the agreement to mutually terminate the collaboration was reached, with a termination date of April 24, 2013, the balance of the deferred revenues and costs that existed at that time on our balance sheet was required to be adjusted to record the cumulative impact of the revised, shorter life of the agreement. 

At September 30, 2012 the balance of deferred revenues related to the Pfizer agreement was $103.4 million and the balance of the deferred costs was $9.3 million.  In the fourth quarter of 2012 the Company recorded $93.6 million in revenue and $8.4 million in cost of goods sold as the amortization of these deferred revenues and costs, respectively.  Had we not reached agreement with Pfizer to mutually terminate the collaboration agreement, we would have recognized $1.6 million and $0.1 million of revenue and costs, respectively.  Therefore, the impact of this change in estimate of the life of the Pfizer collaboration agreement was an increase in 2012 revenues of $92.0 million, cost of goods sold of $8.3 million and net income of $83.7 million, or $1.70 per share, fully diluted (representing the incremental $92.0 million in deferred revenues less the incremental $8.3 million in deferred costs). The remaining deferred revenue and deferred cost balances of $9.8 million and $0.9 million, respectively, will be amortized into our income statement by April 24, 2013, the date that the Pfizer collaboration terminates.

2013 Financial Guidance and non-GAAP MeasuresBeginning in 2013, Auxilium management will be providing certain financial measures on a non-GAAP basis, and is providing financial guidance with respect to certain non-GAAP financial meas
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LUMBY, BC, Sept. 1 /PRNewswire-FirstCall/ - avVaa World Health ... company, manufacturer and distributor of nationally branded therapeutic, natural ... successfully completed its first week of DRTV 120/60 second ... President and COO of avVaa World Health Care Products ...
... Delaware, September 1 According to a new,market research ... http://www.marketsandmarkets.com ), the,global autoimmune treatment market is expected ... CAGR of 12.7% from 2009 to 2014. The North,American ... the total revenues. , Browse ...
... ... + Phillips, Media Investment Bankers, has announced that James R. Brennan, ... IncumediX and COO/CSO at MediServe Information Systems, Jim currently runs a ... acquisitions, technology license and partnership deals, notably the sale of VanSlyck ...
Cached Biology Technology:avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 2DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 3
(Date:4/22/2014)... of breeding bird surveys sent in by citizen scientists ... years, wildlife researchers report that most of the 40 ... higher elevation in response to climate change, but did ... previous studies of potential climate change impacts on wildlife ... have likely underestimated the effects of environmental warming, say ...
(Date:4/22/2014)... is available in French . ... month, sequencing of the complete genome and subsequent phylogenetic ... a clade (variant) that is distinct from strains previously ... Gabon. Epidemiological investigations also linked the laboratory confirmed cases ... outbreak. , Ebola virus is a lethal, highly contagious ...
(Date:4/22/2014)... demonstrate how communities can protect themselves from worsening ... in New England and the Midwest providing practical ... "Our goal is to help communities begin the ... Stack, of Syntectic International, Portland, OR. "It,s important ... move beyond feeling paralyzed from the lack of ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... of the journal Cell Metabolism, published by Cell Press, ... glands of mammals meet the incredible metabolic demands of ... undoubtedly affect breast cancer, the findings may have therapeutic ... one of three “isoforms?of the gene known as Akt ...
... of biologists at New York University's Center for Comparative Functional ... The gene plays a part in ensuring that chromosomes are ... nuclear envelope function. The findings appear in the journal Current ... is using functional genomic tools to study the nematode worm ...
... war against flu, researchers at the University of Wisconsin-Madison ... confers broad protection against influenza viruses, including deadly avian ... (Oct. 4, 2006) in the Journal of Virology, describes ... molecule -- that effectively blocks the influenza virus from ...
Cached Biology News:How mammals fuel milk production may have implications for cancer 2How mammals fuel milk production may have implications for cancer 3NYU biologists identify gene that coordinates two cellular processes 2New drug blocks influenza, including bird flu virus 2New drug blocks influenza, including bird flu virus 3
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: